Novocure (NASDAQ:NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the
Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide
Strong performance drove increased net revenue guidance for full-year 2026 to $736
Novocure (NASDAQ:NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with
Novocure (NASDAQ:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer,
Novocure (NASDAQ:NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.
Novocure management will host a conference call and webcast at 8:00 a.m.
Novocure (NASDAQ:NVCR) announced today that management will participate in two upcoming investor events.
Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will
Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Pax® for the treatment of locally advanced
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR). Such investors are advised to
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR). Such investors are advised to contact
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR). Such investors are advised to
Novocure (NASDAQ:NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.
Novocure management will host a conference call and webcast at 8:00 a.m. EDT,
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR). Such investors are advised to
The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR). Such investors are advised to contact
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or "the Company") (NASDAQ: NVCR) for
